Answers are grounded in this paper and cite their sources.
DXA measures bone density as an absolute measure (g/cm2) and also reports the patient's bone mineral density (BMD) as a comparison to a standard population, which is the basis of the World Health Organization (WHO) classification for osteoporosis. DXA also provides vertebral fracture assessment (VFA), an additional tool to assess vertebral fracture presence and increased fracture risk. Understanding the methodology, reporting, and limitations of DXA use is critical for appropriate utilization of the test. BMD is validated as a predictor of fracture risk and may be used with or without clinical risk factors as part of the FRAX fracture risk assessment tool to accurately assess an individual's fracture risk. In this review, we discuss the role of DXA in screening, diagnosis, and treatment of osteoporosis. We include FRAX and its limitations, trabecular bone score (TBS), quantitative computed tomography (qCT) the American College of Rheumatology (ACR) updates on the management of glucocorticoid-induced osteoporosis, the updated International Society of Clinical Densitometry (ISCD) Position Statements, and report the key features of DXA testing, reporting, and utilization in clinical practice. DXA plays a critical role in BMD evaluation and fracture risk assessment. Appropriate utilization of this tool in clinical practice, through accurate interpretation and application of results, is essential for effective fracture prevention.
No takes yet. Share an insight, caveat, or question.
Anupama et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: